For example, in estrogen receptor ER+ breast cancer, PADI2 can not only promote susceptibility but can also citrullinate histone H3R26, change the structure of nucleosomes, promote the binding of ER and DNA, lead to the activation of ER target genes, and increase the survival rate of ER+ breast cancer patients (57). This evidence concerns the gene PADI2 and breast carcinoma.